| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.453 | 0.004 | 0.453 | Nav1.6 sodium channel blocker | 0.164 0.039 DBMET02061 0.386 0.004 DBMET02062 | ||
| 0.437 | 0.005 | 0.437 | Anesthetic local | 0.134 0.057 DBMET02061 0.35 0.009 DBMET02062 | ||
| 0.41 | 0.005 | 0.41 | Butyrylcholinesterase inhibitor | 0.196 0.022 DBMET02061 0.307 0.01 DBMET02062 | ||
| 0.375 | 0.008 | 0.375 | Ca(v)3.3 blocker | 0.294 0.047 DBMET02061 0.346 0.015 DBMET02062 | ||
| 0.351 | 0.013 | 0.351 | Cholinergic | 0.171 0.062 DBMET02061 0.278 0.022 DBMET02062 | ||
| 0.323 | 0.011 | 0.323 | Acetylcholinesterase inhibitor | 0.161 0.049 DBMET02061 0.257 0.019 DBMET02062 | ||
| 0.294 | 0.009 | 0.294 | Nav1.3 sodium channel blocker | 0.29 0.01 DBMET02062 | ||
| 0.378 | 0.094 | 0.498 | Analgesic | 0.456 0.063 DBMET02061 0.498 0.05 DBMET02062 | DBMET02062 | |
| 0.329 | 0.059 | 0.329 | Spasmolytic | 0.26 0.087 DBMET02062 | ||
| 0.274 | 0.019 | 0.274 | Antipruritic | 0.274 0.019 DBMET02062 | ||
| 0.256 | 0.003 | 0.256 | Guanylate cyclase stimulant | 0.209 0.004 DBMET02061 0.227 0.004 DBMET02062 | ||
| 0.245 | 0.004 | 0.247 | Cannabinoid CB1 receptor agonist | 0.085 0.025 DBMET02061 0.247 0.004 DBMET02062 | DBMET02062 | |
| 0.286 | 0.053 | 0.286 | Vasodilator | 0.245 0.072 DBMET02062 | ||
| 0.337 | 0.106 | 0.337 | Histamine release inhibitor | 0.229 0.172 DBMET02062 | ||
| 0.276 | 0.068 | 0.506 | DNA damaging | 0.506 0.013 DBMET02061 0.247 0.082 DBMET02062 | DBMET02061 | |
| 0.205 | 0.004 | 0.205 | Phosphodiesterase 1A inhibitor | 0.08 0.016 DBMET02061 0.123 0.007 DBMET02062 | ||
| 0.291 | 0.095 | 0.291 | Vasodilator, coronary | 0.258 0.126 DBMET02062 | ||
| 0.253 | 0.065 | 0.253 | Potassium channel blocker | 0.189 0.1 DBMET02061 0.149 0.136 DBMET02062 | ||
| 0.218 | 0.038 | 0.22 | 5 Hydroxytryptamine 3E antagonist | 0.22 0.037 DBMET02062 | DBMET02062 | |
| 0.203 | 0.03 | 0.203 | Arachidonic acid antagonist | 0.153 0.085 DBMET02061 0.163 0.073 DBMET02062 | ||
| 0.184 | 0.011 | 0.184 | ErbB-2 antagonist | 0.107 0.033 DBMET02061 0.162 0.015 DBMET02062 | ||
| 0.271 | 0.099 | 0.271 | Immunomodulator | 0.214 0.148 DBMET02062 | ||
| 0.203 | 0.033 | 0.203 | Nav1.2 sodium channel blocker | 0.193 0.037 DBMET02062 | ||
| 0.176 | 0.009 | 0.176 | Cannabinoid receptor agonist | 0.176 0.009 DBMET02062 | ||
| 0.248 | 0.084 | 0.248 | Cardiotonic | 0.174 0.147 DBMET02062 | ||
| 0.189 | 0.029 | 0.67 | DNA intercalator | 0.67 0.004 DBMET02061 0.094 0.08 DBMET02062 | DBMET02061 | |
| 0.169 | 0.014 | 0.169 | Phosphodiesterase I inhibitor | 0.103 0.041 DBMET02062 | ||
| 0.175 | 0.026 | 0.175 | Antihistaminic | 0.133 0.037 DBMET02062 | ||
| 0.153 | 0.007 | 0.153 | Phosphodiesterase 1B inhibitor | 0.068 0.032 DBMET02062 | ||
| 0.149 | 0.005 | 0.149 | Phosphodiesterase 1C inhibitor | 0.058 0.054 DBMET02061 0.078 0.021 DBMET02062 | ||
| 0.17 | 0.026 | 0.17 | Nav1.1 sodium channel blocker | 0.153 0.032 DBMET02062 | ||
| 0.148 | 0.004 | 0.148 | Guanylate cyclase 1 stimulant | 0.067 0.004 DBMET02061 0.097 0.004 DBMET02062 | ||
| 0.167 | 0.025 | 0.167 | Histamine antagonist | 0.125 0.037 DBMET02062 | ||
| 0.257 | 0.122 | 0.257 | Vasodilator, peripheral | |||
| 0.16 | 0.026 | 0.16 | Protein kinase C gamma inhibitor | 0.129 0.046 DBMET02062 | ||
| 0.149 | 0.018 | 0.149 | ABCA1 expression enhancer | 0.091 0.064 DBMET02061 0.128 0.025 DBMET02062 | ||
| 0.157 | 0.026 | 0.2 | DNA repair enzyme inhibitor | 0.2 0.009 DBMET02061 0.139 0.043 DBMET02062 | DBMET02061 | |
| 0.139 | 0.013 | 0.167 | Histamine H2 receptor antagonist | 0.167 0.007 DBMET02062 | DBMET02062 | |
| 0.129 | 0.004 | 0.129 | CC chemokine 4 receptor antagonist | 0.055 0.021 DBMET02061 0.124 0.004 DBMET02062 | ||
| 0.14 | 0.029 | 0.14 | Sphingomyelinase inhibitor | 0.125 0.038 DBMET02062 | ||
| 0.125 | 0.016 | 0.134 | Lipase inhibitor | 0.089 0.035 DBMET02061 0.134 0.013 DBMET02062 | DBMET02062 | |
| 0.153 | 0.046 | 0.153 | Epidermal growth factor receptor kinase inhibitor | 0.14 0.055 DBMET02061 0.124 0.069 DBMET02062 | ||
| 0.188 | 0.081 | 0.188 | Non-steroidal antiinflammatory agent | 0.186 0.082 DBMET02062 | ||
| 0.134 | 0.028 | 0.134 | Calcium antagonist | |||
| 0.255 | 0.15 | 0.272 | GABA C receptor rho-3 antagonist | 0.272 0.136 DBMET02062 | DBMET02062 | |
| 0.12 | 0.02 | 0.131 | Myeloperoxidase inhibitor | 0.131 0.015 DBMET02062 | DBMET02062 | |
| 0.28 | 0.189 | 0.285 | 5 Hydroxytryptamine release inhibitor | 0.285 0.183 DBMET02062 | DBMET02062 | |
| 0.125 | 0.038 | 0.125 | Creatine kinase inhibitor | 0.101 0.058 DBMET02061 0.107 0.052 DBMET02062 | ||
| 0.184 | 0.101 | 0.232 | HERG channel blocker | 0.232 0.074 DBMET02061 | DBMET02061 | |
| 0.206 | 0.124 | 0.224 | 5 Hydroxytryptamine 1E antagonist | 0.224 0.103 DBMET02062 | DBMET02062 | |
| 0.138 | 0.058 | 0.17 | Antibacterial (Helicobacter pylori) | 0.17 0.033 DBMET02062 | DBMET02062 | |
| 0.152 | 0.072 | 0.152 | Acetylcholine M1 receptor antagonist | 0.117 0.113 DBMET02062 | ||
| 0.127 | 0.047 | 0.143 | Nav1.5 sodium channel blocker | 0.143 0.032 DBMET02062 | DBMET02062 | |
| 0.176 | 0.098 | 0.176 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.169 0.105 DBMET02062 | ||
| 0.111 | 0.035 | 0.111 | Phosphodiesterase 6D inhibitor | 0.091 0.072 DBMET02062 | ||
| 0.279 | 0.203 | 0.315 | MAP kinase 1 inhibitor | 0.315 0.164 DBMET02062 | DBMET02062 | |
| 0.139 | 0.066 | 0.164 | Sodium channel blocker | 0.164 0.048 DBMET02062 | DBMET02062 | |
| 0.131 | 0.057 | 0.131 | Acetylcholine muscarinic antagonist | 0.098 0.093 DBMET02062 | ||
| 0.076 | 0.004 | 0.084 | Guanylate cyclase inhibitor | 0.084 0.002 DBMET02061 0.054 0.017 DBMET02062 | DBMET02061 | |
| 0.108 | 0.036 | 0.108 | ErbB-3 antagonist | 0.087 0.052 DBMET02062 | ||
| 0.138 | 0.069 | 0.138 | Farnesoid X receptor antagonist | 0.132 0.079 DBMET02062 | ||
| 0.079 | 0.013 | 0.087 | 5 Hydroxytryptamine 1B agonist | 0.087 0.01 DBMET02062 | DBMET02062 | |
| 0.077 | 0.011 | 0.077 | Liver X receptor agonist | 0.055 0.019 DBMET02062 | ||
| 0.096 | 0.031 | 0.096 | Acetylcholine M4 receptor antagonist | |||
| 0.105 | 0.041 | 0.105 | Histamine N-methyltransferase inhibitor | |||
| 0.079 | 0.019 | 0.079 | Potassium channel (Ca-activated) blocker | 0.067 0.031 DBMET02062 | ||
| 0.13 | 0.073 | 0.147 | Sphingosine 1-phosphate receptor 2 antagonist | 0.147 0.044 DBMET02062 | DBMET02062 | |
| 0.064 | 0.011 | 0.064 | Liver X receptor alpha agonist | |||
| 0.064 | 0.012 | 0.068 | Benzodiazepine inverse agonist | 0.059 0.015 DBMET02061 0.068 0.01 DBMET02062 | DBMET02062 | |
| 0.086 | 0.033 | 0.086 | Phosphodiesterase VI inhibitor | 0.069 0.064 DBMET02062 | ||
| 0.077 | 0.025 | 0.077 | Prostaglandin F2 alpha antagonist | 0.073 0.029 DBMET02062 | ||
| 0.126 | 0.077 | 0.126 | Toll-Like receptor antagonist | 0.118 0.087 DBMET02062 | ||
| 0.17 | 0.122 | 0.17 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.071 | 0.027 | 0.071 | Calcium channel T-type blocker | |||
| 0.067 | 0.027 | 0.067 | Ca(v)3.2 blocker | |||
| 0.196 | 0.156 | 0.218 | Hypoxia-inducible factor 1 alpha inhibitor | 0.218 0.131 DBMET02061 | DBMET02061 | |
| 0.147 | 0.107 | 0.147 | ATPase inhibitor | 0.139 0.122 DBMET02062 | ||
| 0.105 | 0.066 | 0.105 | Falcipain 3 inhibitor | |||
| 0.052 | 0.013 | 0.052 | Estrogen-related receptor alpha antagonist | 0.035 0.02 DBMET02061 0.042 0.016 DBMET02062 | ||
| 0.048 | 0.009 | 0.089 | ATM kinase inhibitor | 0.089 0.004 DBMET02061 0.041 0.017 DBMET02062 | DBMET02061 | |
| 0.05 | 0.011 | 0.05 | Liver X receptor beta agonist | |||
| 0.08 | 0.041 | 0.08 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.074 0.048 DBMET02062 | ||
| 0.042 | 0.004 | 0.042 | Estrogen-related receptor gamma antagonist | 0.03 0.015 DBMET02062 | ||
| 0.121 | 0.083 | 0.149 | Sodium channel (voltage-gated) blocker | 0.149 0.055 DBMET02062 | DBMET02062 | |
| 0.059 | 0.022 | 0.059 | Histamine H3 receptor antagonist | 0.044 0.03 DBMET02062 | ||
| 0.089 | 0.054 | 0.089 | Epidermal growth factor antagonist | 0.089 0.054 DBMET02061 | ||
| 0.072 | 0.039 | 0.072 | 5 Hydroxytryptamine 3A antagonist | 0.059 0.057 DBMET02062 | ||
| 0.057 | 0.027 | 0.057 | 5 Hydroxytryptamine 4 antagonist | 0.054 0.031 DBMET02062 | ||
| 0.045 | 0.015 | 0.055 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | 0.055 0.009 DBMET02061 | DBMET02061 | |
| 0.118 | 0.089 | 0.118 | Calcium channel blocker | |||
| 0.158 | 0.13 | 0.187 | Potassium channel (Voltage-sensitive) blocker | 0.187 0.105 DBMET02061 | DBMET02061 | |
| 0.053 | 0.025 | 0.053 | Cholesterol esterase inhibitor | 0.047 0.034 DBMET02062 | ||
| 0.264 | 0.237 | 0.264 | Caspase 9 stimulant | |||
| 0.074 | 0.052 | 0.107 | Protein kinase B gamma inhibitor | 0.107 0.029 DBMET02062 | DBMET02062 | |
| 0.087 | 0.066 | 0.087 | Hepatocyte growth factor antagonist | 0.078 0.077 DBMET02062 | ||
| 0.07 | 0.05 | 0.07 | Phosphodiesterase 5A inhibitor | |||
| 0.071 | 0.051 | 0.071 | Phosphodiesterase V inhibitor | |||
| 0.094 | 0.074 | 0.094 | Gastric antisecretory | 0.092 0.076 DBMET02062 | ||
| 0.096 | 0.077 | 0.096 | Granulocyte macrophage colony stimulating factor antagonist | 0.089 0.086 DBMET02062 | ||
| 0.041 | 0.023 | 0.041 | CF transmembrane conductance regulator antagonist | |||
| 0.047 | 0.029 | 0.047 | Potassium channel small-conductance Ca-activated blocker | 0.044 0.032 DBMET02062 | ||
| 0.1 | 0.082 | 0.1 | Electron transport complex I inhibitor | |||
| 0.081 | 0.063 | 0.081 | Estrogen-related receptor beta agonist | |||
| 0.044 | 0.026 | 0.049 | Angiotensin AT1 receptor antagonist | 0.049 0.02 DBMET02062 | DBMET02062 | |
| 0.179 | 0.162 | 0.179 | Neuropeptide Y2 antagonist | |||
| 0.03 | 0.013 | 0.03 | Myristoyl transferase inhibitor | 0.03 0.013 DBMET02062 | ||
| 0.05 | 0.036 | 0.05 | Cannabinoid CB2 receptor antagonist | 0.047 0.039 DBMET02062 | ||
| 0.059 | 0.045 | 0.059 | Bcl-xL inhibitor | |||
| 0.046 | 0.033 | 0.046 | Phosphodiesterase 6C inhibitor | |||
| 0.11 | 0.097 | 0.116 | Toll-Like receptor 9 antagonist | 0.116 0.09 DBMET02062 | DBMET02062 | |
| 0.06 | 0.048 | 0.06 | 5 Hydroxytryptamine 3 agonist | |||
| 0.052 | 0.04 | 0.052 | Cannabinoid CB2 receptor agonist | 0.048 0.044 DBMET02062 | ||
| 0.065 | 0.054 | 0.065 | 5 Hydroxytryptamine 1F antagonist | |||
| 0.148 | 0.137 | 0.148 | Insulin sensitizer | |||
| 0.048 | 0.037 | 0.048 | Prostaglandin E2 antagonist | 0.044 0.042 DBMET02062 | ||
| 0.029 | 0.019 | 0.029 | 5 Hydroxytryptamine 1D agonist | |||
| 0.149 | 0.14 | 0.149 | Aldehyde oxidase inhibitor | |||
| 0.123 | 0.114 | 0.123 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | |||
| 0.097 | 0.089 | 0.097 | Calcium channel (voltage-sensitive) blocker | |||
| 0.102 | 0.095 | 0.102 | Sphingosine 1-phosphate receptor 2 agonist | |||
| 0.026 | 0.02 | 0.026 | Urotensin II agonist | |||
| 0.057 | 0.051 | 0.057 | 5 Hydroxytryptamine 5A antagonist | |||
| 0.032 | 0.027 | 0.037 | Angiotensin II receptor antagonist | 0.037 0.018 DBMET02062 | DBMET02062 | |
| 0.139 | 0.134 | 0.144 | Succinate dehydrogenase inhibitor | 0.144 0.124 DBMET02062 | DBMET02062 | |
| 0.149 | 0.146 | 0.149 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | |||
| 0.099 | 0.097 | 0.099 | Cholinergic antagonist | |||
| 0.195 | 0.195 | 0.221 | Sodium/bile acid cotransporter inhibitor | 0.221 0.161 DBMET02062 | DBMET02062 | |
| 0.037 | 0.039 | 0.059 | Histamine H2 receptor agonist | 0.059 0.015 DBMET02062 | DBMET02062 | |
| 0.031 | 0.035 | 0.181 | Kinesin antagonist | 0.181 0.004 DBMET02061 | DBMET02061 | |
| 0.031 | 0.035 | 0.181 | Kinesin-like protein 1 inhibitor | 0.181 0.004 DBMET02061 | DBMET02061 | |
| 0.039 | 0.053 | 0.045 | 5 Hydroxytryptamine 2 agonist | 0.045 0.044 DBMET02062 | DBMET02062 | |
| 0.081 | 0.116 | 0.126 | Alkylator | 0.126 0.062 DBMET02061 | DBMET02061 | |
| 0.02 | 0.057 | 0.035 | Melatonin 2 agonist | 0.035 0.02 DBMET02062 | DBMET02062 | |
| 0.034 | 0.078 | 0.048 | Histamine agonist | 0.048 0.043 DBMET02062 | DBMET02062 | |
| 0.065 | 0.11 | 0.106 | Topoisomerase I inhibitor | 0.106 0.065 DBMET02061 | DBMET02061 | |
| 0.06 | 0.116 | 0.096 | Bronchodilator | 0.096 0.069 DBMET02062 | DBMET02062 | |
| 0.105 | 0.164 | 0.142 | GABA C receptor rho-2 antagonist | 0.142 0.084 DBMET02062 | DBMET02062 | |
| 0.242 | 0.301 | 0.334 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.334 0.17 DBMET02062 | DBMET02062 | |
| 0.098 | 0.177 | 0.151 | Hemostatic | 0.151 0.067 DBMET02062 | DBMET02062 | |
| 0.039 | 0.159 | 0.098 | Telomerase inhibitor | 0.098 0.034 DBMET02061 | DBMET02061 | |
| 0.094 | 0.218 | 0.137 | I kappa B kinase epsilon inhibitor | 0.137 0.135 DBMET02062 | DBMET02062 | |
| 0.064 | 0.191 | 0.105 | Glutamate (mGluR7) agonist | 0.105 0.05 DBMET02062 | DBMET02062 | |
| 0.018 | 0.15 | 0.06 | 5 Hydroxytryptamine uptake inhibitor | 0.06 0.047 DBMET02061 | DBMET02061 | |
| 0.06 | 0.196 | 0.16 | Toll-Like receptor 3 antagonist | 0.16 0.012 DBMET02062 | DBMET02062 | |
| 0.029 | 0.182 | 0.066 | Protein kinase C alpha inhibitor | 0.066 0.05 DBMET02061 | DBMET02061 | |
| 0.023 | 0.196 | 0.115 | Adrenaline uptake inhibitor | 0.115 0.015 DBMET02061 0.072 0.033 DBMET02062 | DBMET02061 | |
| 0.02 | 0.237 | 0.115 | Check point kinase 1 inhibitor | 0.115 0.022 DBMET02061 | DBMET02061 | |
| 0.109 | 0.368 | 0.211 | Peptidyltransferase inhibitor | 0.211 0.086 DBMET02062 | DBMET02062 | |
| 0.016 | 0.28 | 0.105 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.105 0.033 DBMET02061 | DBMET02061 | |
| 0.13 | 0.465 | 0.483 | Calcium channel L-type activator | 0.483 0.035 DBMET02062 | DBMET02062 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |